• Publications
  • Influence
Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
BACKGROUND Mometasone furoate (MF; Schering-Plough, Madison, NJ), is a glucocorticoid with high local potency and low potential systemic availability. OBJECTIVES To compare the relative efficacyExpand
  • 58
  • 6
Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety
Antihistamines are widely used to treat allergic rhinitis (AR) and chronic idiopathic urticaria (CIU) in adults and children. Desloratadine is a once-daily oral antihistamine with a favourableExpand
  • 26
  • 6
Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group.
BACKGROUND Mometasone furoate (Nasonex), in a new once-daily aqueous nasal spray formulation, has been shown to be as effective and well-tolerated as twice-daily beclomethasone dipropionate aqueousExpand
  • 84
  • 5
Desloratadine therapy for symptoms associated with perennial allergic rhinitis.
BACKGROUND Perennial allergic rhinitis (PAR) has a substantial negative social and economic impact. Recent studies emphasize the potential seriousness of PAR and the need for improved treatment ofExpand
  • 50
  • 4
Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler.
Mometasone furoate (MF) administered by dry powder inhaler (DPI) was composed with budesonide (BUD) Turbuhaler in the treatment of moderate persistent asthma. The patients were randomized to one ofExpand
  • 58
  • 4
Assessment by Nasal Biopsy of Long-Term Use of Mometasone Furoate Aqueous Nasal Spray (Nasonex) in the Treatment of Perennial Rhinitis
Allergic rhinitis is associated with specific histopathologic changes in the nasal mucosa including squamous metaplasia and local eosinophilia. Previous studies have shown that mometasone furoateExpand
  • 138
  • 3
Once‐daily mometasone furoate aqueous nasal spray (Nasonex®) in seasonal allergic rhinitis: an active‐ and placebo‐controlled study
Mometasone furoate aqueous nasal spray (Nasonex®) was compared with beclomethasone dipropionate (BDP) aqueous nasal spray in a double‐blind, randomized, placebo‐controlled, double‐dummy,Expand
  • 90
  • 3
Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients.
BACKGROUND Perennial allergic rhinitis is chronic and persistent, may lead to a constellation of secondary complaints including sinusitis, mouth-breathing, and some symptoms resembling a permanentExpand
  • 71
  • 3
Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group.
BACKGROUND Mometasone furoate (Nasonex), in a new once-daily aqueous nasal spray formulation, has been shown to be as effective and well-tolerated as twice-daily beclomethasone dipropionate aqueousExpand
  • 40
  • 3
Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler.
BACKGROUND Once-daily dosing with an effective inhaled corticosteroid (ICS) would likely enhance compliance and, therefore, aid in the management of asthma. OBJECTIVE Several once-daily dosingExpand
  • 76
  • 2